Below are select publications outlining recent advancements in Alzheimer’s Disease research from NYSCF Innovators.
CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2N141I neurons.
Ortiz-Virumbrales M, Moreno CL, Kruglikov I, Marazuela P, Sproul A, Jacob S, Zimmer M, Paull D, Zhang B, Schadt EE, Ehrlich ME, Tanzi RE, Arancio O, Noggle S, Gandy S.
Acta Neuropathologica Communications. 2017. doi: 10.1186/s40478-017-0475-z.
In this study, NYSCF scientists in collaboration with researchers at the Icahn School of Medicine at Mount Sinai refined a technique to turn skin cells from patients with mild cognitive impairment into the brain cells that degenerate first in Alzheimer’s disease.
Characterization and Molecular Profiling of PSEN1 Familial Alzheimer’s Disease iPSC-Derived Neural Progenitors.
Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, Santa-Maria I, Zimmer M, Aubry S, Steele JW, Kahler DJ, Dranovsky A, Arancio O, Crary JF, Gandy S, Noggle SA.
PLoS One. 2014. doi: 10.1371/journal.pone.0084547.
This study outlines how NYSCF scientists in collaboration with scientists at the Icahn School of Medicine at Mount Sinai successfully generated a stem cell model of familial Alzheimer’s disease and identified genes that contribute to its pathology and onset.
Generation of iPSC lines from archived non-cryoprotected biobanked dura mater.
Sproul AA, Vensand LB, Dusenberry CR, Jacob S, Vonsattel JP, Paull DJ, Shelanski ML, Crary JF, Noggle SA.
Acta Neuropathologica Communications. 2014. doi: 10.1186/2051-5960-2-4
This paper details how NYSCF scientists were able to generate induced pluripotent stem cell lines from bio-banked tissue taken from Alzheimer’s patients.